Research Triangle Park’s Post

Kim Boericke is the Chief Operating Officer of THREAD, driving innovation, fostering a patient-centric approach, and streamlining operations to revolutionize the world of clinical trials. Read More: https://bityl.co/NjPS #technologysolutions #techsolutions #innovation #clinicaltrials #technology #researchanddevelopment #RandD #research #development #insightssuccess

Kim Boericke is the Chief Operating Officer of THREAD, driving innovation, fostering a patient-centric approach, and streamlining operations to revolutionize the world of clinical trials. Read More: https://bityl.co/NjPS #technologysolutions #techsolutions #innovation #clinicaltrials #technology #researchanddevelopment #RandD #research #development #insightssuccess

🌟 Weekly Recap: A Week of Collaboration, and Celebration! 🌟 Last week was packed with exciting moments for NLC with HLTH, an exclusive networking dinner, successful ortho/spine panel and a festive venture day. Here's a look back at everything we had done: June 17-20: HLTH Europe We had an incredible time showcasing our health innovations at HLTH Europe. Throughout the week NLC pavilion was filled with inspiring discussions, valuable insights from venture CEOs, and a deep dive into cardiovascular, biotech, ortho/spine and general health tech solutions. It was a fantastic opportunity to connect with industry leaders and explore collaborative opportunities. June 18: Exclusive Networking Dinner We also hosted an exclusive dinner, bringing together decision-makers from the biotech, cardiovascular, ortho-spine, and general health industries. The evening was filled with enriching conversations, networking and great food. June 19: Ortho & Spine Expert Panel Besides growing our community and network, we have also engaged in meaningful discussion with professionals from our Ortho & Spine Expert Panel on technologies currently in our venture creation pipeline. We also invited three of our ventures to share their questions with the experts, as challenges and questions will continue to arise even after the venture is established. June 21: Venture Day  Wrapping up the week, we hosted the annual Venture Day, uniting NLC’s ventures from around the globe. We covered critical topics such as early-stage funding, clinical trials, market access, and more. The event concluded with a graduation ceremony celebrating the achievements of Mitracept , Aerion Bioscience, ChARM, and Neurolieve Biosciences Ltd. Here's to many more fruitful weeks ahead, and cheers to transforming healthcare! 🚀 #HealthcareInnovation #HLTHEurope #VentureDay #Networking #Healthtech #Medtech #Biotech #Cardiovascular #OrthoSpine #PanelDiscussion

🤠 Move over, cowboy culture—Texas is actually a big contender in the life sciences industry! 👩🎓 The Lone Star State boasts 15 medical universities, 7 in the top 125, and over 2,000 biotech R&D firms. 📝It's a hub of innovation, leading the nation in health science doctorates and clinical trials. 💡In the past 5 years, North Texas has drawn in ~$4.5B in private capital, with 52 acquisitions and IPOs. 🐴 Dallas shines with the highest net migration and a strong STEM graduate output, fueling industry growth by over 15%. 🌱 The ecosystem is ripe with incubators, like the Texas Research Quarter in Plano, set to be a 4-million-square-foot life science campus. 🤝 It's about community, too. Groups like BioHouston and BioNTX are key in fostering a collaborative spirit. 🏢 Missing your logo? Drop your company in the comments! #CDMO #lifescience #texas

The UK and Ireland: Hotspots of Medical Device and Technology Innovation It's an incredibly exciting time for the medical devices and technology sectors in the UK and Ireland. These regions are experiencing unprecedented growth and quickly becoming global hubs for healthcare innovation. Let's unpack some drivers behind this impressive momentum: 👨🔬 World-Class Talent and Research: Renowned universities in these countries attract and train top talent in medicine, engineering, and technology. This, coupled with cutting-edge research facilities, drives groundbreaking advancements in medtech. 🤝 Supportive Ecosystems: Both the UK and Ireland foster collaborative environments between investors, established companies, universities, and promising startups. This robust support system nurtures innovation and accelerates the development of new solutions. 🏦 Government Backing: Strong government initiatives focused on life sciences and healthcare encourage R&D investments and adoption of novel technologies, bolstering the medical devices and tech sectors. The Real-World Impact This boom is about more than just statistics. From advanced prosthetics to AI-powered diagnostics, innovations developed in the UK and Ireland are revolutionizing patient care. Every day, we see firsthand how these groundbreaking advancements lead to improved patient outcomes and transformed lives. If you're passionate about making a difference in healthcare, now is the time to be a part of this growth. Whether you're a researcher, developer, entrepreneur, or healthcare professional, the UK and Ireland offer boundless opportunities to shape the future of medicine. Let's Connect! Are you involved in the medtech field within Regulatory Affairs or Quality? Send me a message and let's have a chat. #medtech #innovation #healthcare #UK #Ireland

Did you know that we work with over 50 medical institutions across the globe, from 36 countries? These partnerships are crucial in healthcare, where groundbreaking advancements and improved patient outcomes rely so much on collaboration. Each of our 50+ partnering institutions specializes in a unique area of medicine, research, or patient care, which enhances Cure51’s knowledge and capabilities. This diversity encourages collaboration and knowledge sharing, which ultimately accelerates the pace of innovation, which is what counts in our battle to defeat cancer in our lifetime. By pooling together the resources and talents of 50 institutions and growing every day, Cure51 has access to a vast network of facilities, patient populations, and research labs. This enables more extensive clinical trials, broader data collection, and more robust multimodal analysis, all of which are crucial for generating conclusive findings and translating them into clinical care. On top of that, partnerships provide a platform for sharing best practices, standardizing protocols, and disseminating knowledge across the network. Partners now have the opportunity to learn from each other's successes and failures, refine their approaches, and continuously improve the quality of care they deliver. It’s as if Samsung, Apple and Huawei were working together! Finally, partnerships enhance the visibility and credibility of Cure51 within the broader healthcare community. By aligning with reputable institutions and thought leaders in the field, Cure51 gains legitimacy and trust among patients, healthcare professionals, policymakers, and philanthropic organizations. This, in turn, facilitates fundraising efforts, attracts top talent, and opens doors to new opportunities for collaboration and expansion. We are beyond thrilled that Cure51 represents a powerful scientific alliance dedicated to advancing medical knowledge, improving patient care, and ultimately, transforming lives. Through collaboration, innovation, and shared values, these partners are driving progress towards a healthier and more equitable future for all. HOPE IS FOR EVERYONE #oncology #drugdiscovery #biotechnology #cancersurvivor #outliers #healthtech  #biotech  #cancerresearch 

Crucial information if you’re in #medtech and looking for #funding but, as you can see below, there isn’t much time left.

This interview with David Hochman from Orchestra BioMed, exemplifies the power of innovative partnerships in the medical device industry. Hochman's vision of breaking barriers and fostering a win-win scenario resonates deeply. It's not just about creating high-impact devices; it's about optimising the entire process, from idea to market, ensuring benefits for patients and other stakeholders. Here are my Key takeaways: 1. Power of Partnership: A key learning from David's experience emphasises the creative structuring of partnerships and business models and how one can leverage creativity to build collaborative structures that align with long-term goals, fostering a win-win scenario for all stakeholders. Effective collaboration can break barriers and drive innovation. 2. Adaptability Amid Industry Shifts: The landscape of device innovation shifted in 2008, posing challenges. The determination to reevaluate approaches and draw inspiration from the biotech industry's partnership-driven model showcases the need for adaptability and the ability to create strategic pivots for impact. Being responsive to industry shifts is crucial for sustained success. 3. Team Expertise & Passion: Passionate individuals working towards a shared vision are a driving force behind impactful research, development, and clinical trials. 4. Inspiration Through Alternative Approaches: David's aspiration to inspire the industry by proving that alternative approaches yield success challenges the status quo, reiterating the importance of innovation and looking beyond traditional norms to drive meaningful change. 5. Balancing Long-Term Vision: Prioritising a long-term outlook over short-term gains is a crucial insight. Cutting corners compromises milestones, especially in complex processes like clinical trials. This emphasises the importance of patience and strategic foresight in achieving regulatory goals. https://lnkd.in/eZxtZReH #MedTechInnovation #CEOInsights #CollaborativeLeadership Avegen #digitalhealth

How can we transform public healthcare dollars into innovative, commercialized healthcare technologies? The Ontario Government | Gouvernement de l’Ontario Entrepreneur-In-Residence program supports this vision, funding initiatives from AI-driven tools to regenerative therapies that promise to revolutionize patient care and stimulate economic growth. Your thoughts? #HealthcareInnovation #Ontario #PublicHealth #Commercialization

Maybe it's time to look beyond Oxford and Cambridge.? ''The UK has a very healthy life sciences sector, worth around £94 billion a year and employing 300,000 people, focussed inevitably on Oxford and Cambridge. It is estimated that two-thirds of all life sciences startups in Europe are formed in the UK. Yet in both cities developers say the planning system, lack of council resources and local opposition to developments make it impossible to put up new facilities to cope with surging demand. In both cities, developers are repurposing defunct retail and office facilities in an effort to keep up with demand.'' https://lnkd.in/eHN7C-r3 348/365